VANCOUVER, July 6 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the “Company”) , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, announced today that the Company’s Director of Preclinical Drug Development, Donald Wong, Ph.D., will be a featured presenter at the 8th Annual Anti-Cancer Drug Discovery & Development Summit in Boston, Massachusetts.
WHEN: Tuesday, July 18, 2006 at 2:00pm EDT WHERE: Hilton Boston Back Bay 40 Dalton Street Boston, Massachusetts WHAT: Dr. Wong’s presentation is entitled “A Rationally Designed Chemokine Stromal Cell Derived Factor 1 (SDF-1) Antagonist is a Potent Inhibitor of Cancer Metastasis and Angiogenesis”. About Strategic Research Institute
The Strategic Research Institute’s globally recognized conferences provide powerful business research, education, and information, which relate directly to market trends, global competition and technological change. These conferences also provide a forum for face-to-face networking between industry leaders, potential strategic partners, prospects and customers.
For more information, please visit: http://www.srinstitute.com/conf_page.cfm?instance_id=27&web_id=835&pid=442.
About Chemokine Therapeutics Corp.
Chemokine Therapeutics is a product-focused biotechnology company developing drugs in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, and stem cells, as well as tissue repair and regeneration. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development. For more information, please visit the Company’s website at www.chemokine.net.
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding managements’ future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “projects”, and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company’s products, the availability of government and insurance reimbursements for the Company’s products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company’s public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT: Elite Financial Communications Group, Chemokine Investor Relations, Dodi Handy, President & CEO, Phone: (407) 585-1080, E-mail: chkt@efcg.net
Chemokine Therapeutics Corp.
CONTACT: Elite Financial Communications Group, Chemokine InvestorRelations, Dodi Handy, President & CEO, Phone: (407) 585-1080, E-mail:chkt@efcg.net
